Life Sicences - Intro
A golden age in pharma?
Discoveries. Breakthroughs. Innovations. The life sciences sector is a promising landscape filled with opportunity.
Today, advances in the life sciences and the accelerating evolution of computing, automation, and artificial intelligence are fueling a new wave of innovation—faster than ever before—aimed at driving better health outcomes.
Our suite of MSCI Life Sciences Indexes aims to represent long-term, future-focused themes that are expected to disrupt the life sciences, biotechnology and pharmaceutical industries. These indexes can be used to benchmark growth, facilitate portfolio construction, enhance research or support new product development. They are designed to measure performance of companies delivering exciting health-focused solutions, and to help investors focus on trends shaping tomorrow.
Life Sciences - Video
Life Sciences - Our offerings 2023
Bringing together our data and insight, with the industry expertise of Royalty Pharma, our new indexes focus on the biopharmaceutical and life sciences disruption. From preventative and personalized medicines to cancer breakthroughs, new antivirals and digitized assessment, diagnosis and treatments, our initial indexes are focused on virology, immuno-oncology and broad biotech.
- MSCI Biotech Advance Indexes: Aim to represent the performance of a set of companies that are associated with research, development, and commercialization of products for treating a broad range of diseases and disorders. Methodology (PDF, 223 KB)
- MSCI Virology Index: Aims to represent the performance of a set of companies that are associated with research and development into, as well as the commercialization of anti-viral and vaccine products
- MSCI Immuno-oncology Index: Aims to represent the performance of a set of companies that are associated with research, development, and commercialization of products for cancer immunotherapy
Life Sciences - Featured content
The pharmaceutical industry is experiencing a faster pace of disruption thanks to frequent technological breakthroughs. This results in more innovative treatments being developed, and in less time than ever before.
MSCI Thematic Insight: Immuno-Oncology: Harnessing Immunity in the Fight Against Cancer
(PDF, 5.6 MB) (opens in a new tab)
Despite many recent advances that have revolutionized cancer care for patients, oncology remains one of the areas with the largest unmet need in medicine. The field of immuno-oncology is now consolidating its presence in the frontline of treatments for most major types of cancer.
The global population is growing and ageing. To match it, there’s a faster pace of disruption, with a greater number of breakthroughs in less time than ever before.